Podcasts about Novo Nordisk

SpaceX on the move in after-hours trading on the back of its first earnings report since going public. Can investors expect SpaceX to blast off, or will the aerospace giant sink even further below its IPO price?Then, major Pharma earnings from giants like Pfizer and Merck beating Wall Street estimates with Amgen and Eli Lilly on deck. Founder and CEO of Portal Innovations John Flavin lays out the best trades in the Pharma market, and his reaction to Novo Nordisk's slide after disappointing guidance. Plus, why Morgan Stanley is bearish on AMD, digging into Caterpillar earnings, and can McDonald's make a comeback? Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Novo Nordisk's CEO checks in on his first year at the helm, and Russia is quietly assembling a "shadow fleet" of ships to circumvent EU sanctions. Plus, we take a deep dive into a historic joint intervention in Japan's currency.Mentioned in this podcast:‘Arrogance kills': Novo chief injects risk-taking into Ozempic-makerAstraZeneca investors raise concerns over mega-merger talksRussia expands shadow LNG fleet ahead of EU banTeam America: Yen policeJapan vows further yen intervention with US if neededListen to Unhedged on Apple Podcasts, Pocket Casts or Spotify.Want to get in touch? Email us at podcasts@ft.comNote: The FT does not use generative AI to voice its podcasts The FT News Briefing is produced by Victoria Craig, Sonja Hutson, Saffeya Ahmed and Katya Kumkova. Our editor is Marc Filippino. Our show is mixed by Sam Giovinco and Alex Higgins. Additional help from Gavin Kallmann, Michael Lello, Peter Barber and David da Silva. Our intern is Cole van Miltenburg. Special thanks to Nisha Patel. Our executive producer is Topher Forhecz. Flo Phillips is the FT's global head of audio. The show's theme music is by Metaphor Music. Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Today, a look at the broad market in a positive mood as recent divergences between AI hardware and other names were nowhere in evidence. We zoom in on Palantir's incredible quarterly reports and the wild and entertaining earnings call with CEO Alex Karp, wonder how SpaceX can deliver anything notable today relative to the company's valuation, and preview AMD, Novo Nordisk and Eli Lilly, all with Saxo Equity Strategist Ruben Dalfovo. Macro and FX and more also on today's pod, which was hosted by Saxo Global Head of Macro Strategy John J. Hardy. Links Yesterday's John J. Hardy substack post with many links, including on AI. John's The FX Trader piece from this morning, focusing especially on the recent coordinated JPY intervention and EURJPY. 69 Starship launches to get one decent payload to the moon? A Starship skeptic speaks out on concerns related to the idea of SpaceX using these space-based depots of fuel to extend the operating range of Starship.  Arnaud Bertrand challenges Palantir's AI Sovereignty framework, although Palantir's results spoke quite loudly late yesterday, as did CEO Alex Karp himself. Tungsten as an indicator of war risk and once again, a mineral supply chain that China dominates. About twice per week (in normal times, hopefully soon to resume), you will find links discussed on the podcast and a chart-of-the-day over at the John J. Hardy substack. Read daily in-depth market updates from the Saxo Market Call and the Saxo Strategy Team here. Please reach out to us at marketcall@saxobank.com for feedback and questions. Click here to open an account with Saxo. Intro music by AShamaluevMusic DISCLAIMER This content is marketing material. Trading financial instruments carries risks. Always ensure that you understand these risks before trading. This material does not contain investment advice or an encouragement to invest in a particular manner. Historic performance is not a guarantee of future results. The instrument(s) referenced in this content may be issued by a partner, from whom Saxo Bank A/S receives promotional fees, payment or retrocessions. While Saxo may receive compensation from these partnerships, all content is created with the aim of providing clients with valuable information and options.  

Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China's pharmaceutical industry becomes increasingly important, Novo may be staring at a very uncomfortable question: what happens if synthetic semaglutide suddenly makes sense when Novo is the one making it?In this week's episode of The Weekly Dose, I dig into Novo's long-running recombinant-versus-synthetic semaglutide argument, the lawsuits and FDA petitions built around it, and a clip from more than 16 months ago showing that we were covering this exact issue long before it became part of the mainstream conversation. Novo Warned Us About Synthetic Semaglutide_ Now This_.txtWe also break down Pfizer's decision to kill two clinical-stage obesity drugs, including an oral GLP-1 acquired through its $10 billion Metsera deal, the strange science behind GIP receptor antagonism, and why Pfizer's remaining obesity pipeline still deserves attention. Plus, Wall Street is looking at Eli Lilly's obesity-fueled rally and asking just how big this market can get.In this episode:00:00 Novo's synthetic semaglutide problem02:00 VoaFit sponsor message03:30 The 16-month-old On The Pen receipt05:00 Recombinant vs. synthetic semaglutide07:00 Novo's FDA, legal, and political strategy09:00 Pfizer kills two obesity drugs11:00 What happened to Metsera's oral pipeline?13:00 The GIP agonist vs. antagonist paradox15:00 Why China matters to Pfizer and Novo17:00 Could Novo eventually make synthetic semaglutide?18:30 What comes next for Lilly, Novo, and PfizerThe big question: If Novo Nordisk eventually launches its own synthetically manufactured semaglutide, does that change how you view the arguments it has made against compounded semaglutide over the last several years?Comment below. I want to know where you land.More obesity medicine news and analysis: OnThePen.comAll my links, socials, and resources: linktr.ee/manonthemounjaroThis episode is sponsored by VoaFit. Learn more at voafit.com/otp.#GLP1 #Semaglutide #Ozempic #Wegovy #NovoNordisk #CompoundedSemaglutide #ObesityMedicine #Pfizer #EliLilly #Mounjaro #Zepbound #Metsera

2,5% Zinsen p.a. auf ein unbegrenztes Guthaben mit bis zu fünfmal der gesetzlichen Einlagensicherung*. Auch für Kinder. Das gibt's bei Scalable Capital. Mehr Infos hier.Trump stoppt Iran-Angriff. Amazon, Microsoft & Alphabet legen 1.500 Mrd. $ zu. Roblox, Reddit & Universal Music crashen über 20%. Novo Nordisk fällt wegen Studien-Flop. Schaeffler kappt Prognose. Alimentation Couche-Tard will Zabka.Perimeter Solutions (WKN: A40PUQ) hat quasi ein Monopol auf Löschmittel aus der Luft. Dahinter steckt TransDigm-Gründer Nick Howley. Starke Marktstellung, aber das Feuergeschäft stagniert trotz Brandsaison.CATL (WKN: A418NB) baut nicht nur E-Auto-Batterien. Back-Up-Batterien für KI-Rechenzentren boomen, Umsatz mit Speichern fast verdoppelt. Dazu Natrium-Batterien und über 150 Beteiligungen. Erwartetes KGV liegt bei 20.Diesen Podcast vom 03.08.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. *Veränderlicher Zins auf unbegrenztes Guthaben. Konditionen sowie Guthabenverteilung auf scalable.capital/tagesgeld. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent weeks have been a whirlwind of activity in the pharmaceutical and biotech sectors, showcasing significant strides in scientific breakthroughs, regulatory advancements, and strategic industry maneuvers. Replimune's Vusolimogene Oderparepvec has emerged as a beacon of hope in the fight against advanced melanoma. This gene therapy, utilizing an oncolytic virus, has recently received a positive nod from an advisory committee for its Phase 1/2 trial. When combined with PD-1 checkpoint inhibitors, it holds promise for enhancing immune responses against tumors—a critical development in cancer treatment that may redefine therapeutic strategies. This advancement follows two prior FDA rejections, underscoring the multifaceted evaluation process drugs undergo before approval and demonstrating that perseverance can eventually lead to success. Meanwhile, AstraZeneca and Daiichi Sankyo have achieved a milestone with the European Union's approval of Datopotamab Deruxtecan for treating unresectable or metastatic triple-negative breast cancer (TNBC). As an antibody-drug conjugate targeting the Trop-2 protein, it offers new hope to TNBC patients who often have limited options. This approval underscores the potential of antibody-drug conjugates in oncology, supported by promising Phase 3 trial data. Regeneron Pharmaceuticals is enjoying notable revenue growth thanks to Dupixent, a monoclonal antibody addressing autoimmune and respiratory diseases. Such financial success underscores the expanding role of biologics in tackling chronic illnesses, reflecting a broader industry trend towards biologically-based treatments. In business news, Pharmanovia's licensing deal with Impact Therapeutics for Senaparib signifies strategic expansion in oncology therapeutics. Similarly, Kaigene's agreement with Taisho Pharmaceutical highlights ongoing interest in autoimmune therapies, illustrating how companies are leveraging partnerships to broaden their therapeutic horizons. Pfizer is on the brink of expanding its label for Ritlecitinib (Litfulo), a JAK3 inhibitor that showed positive results in Phase 3 trials for nonsegmental vitiligo. By targeting autoimmune pathways, this small molecule could offer new hope to vitiligo patients seeking effective treatments. Litfulo is advancing through regulatory stages following successful trials, poised to provide an oral alternative for non-segmental vitiligo—a potential game-changer that could improve patient compliance and expand treatment options beyond Incyte's Opzelura. However, not all news is positive. Novo Nordisk faced disappointment when its Ziltivekimab failed a Phase 3 trial for atherosclerotic cardiovascular disease with chronic kidney disease. Despite this setback, Novo Nordisk remains optimistic about ongoing trials Artemis and Hermes as potential lifelines for their CKD program. Success could diversify their portfolio and introduce novel therapeutic options for CKD patients. Additionally, financial hurdles surfaced as Daiichi Sankyo saw an 11% share drop due to an accounting error, and Alnylam Pharmaceuticals' market value took a hit following a lowered revenue forecast for its TTR drug. On a global scale, the Trump administration has allocated $600 million to GAVI for childhood immunizations worldwide. This funding reversal emphasizes ongoing efforts to ensure vaccine accessibility across the globe—an essential component of public health initiatives. The dynamic nature of these developments reflects both the potential and challenges within the pharmaceutical landscape. The promising avenues presented by gene therapy, antibody-drug conjugates, and JAK inhibitors are tempered by clinical setbacks and financial volatility, underscoring the rigorous demands faced by industry stakeholders. In other industry news, AbbVie's Skyrizi continues to thrive despite increasing competition in the psoriasis market. With sales reaching $5.55 billion in Q2 2026, Skyrizi demonstrates the sustained demand for innovative biologics that enhance treatment efficacy and safety profiles. Karyopharm Therapeutics remains committed to its XPO1 inhibitor Xpovio despite setbacks in other indications like endometrial cancer. Their focus on myelofibrosis illustrates a strategic pivot towards hematologic malignancies where unmet needs persist. Oral GLP-1 receptor agonists are gaining ground as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie for dominance in weight management solutions. These oral formulations promise increased accessibility over traditional injectables. Regulatory arenas continue to evolve with AbbVie's Rinvoq gaining European clearance for alopecia and vitiligo. Such approvals highlight regulatory bodies' critical role in expanding market access across diverse therapeutic areas. Strategic partnerships also abound as WellSpan Health collaborates with Hippocratic AI to integrate artificial intelligence into healthcare solutions—a growing trend aimed at enhancing clinical decision-making capabilities. Meanwhile, Apnimed's $192 million IPO success indicates strong investor confidence in novel therapeutics like its sleep apnea treatment—a reflection of biopharma's financing dynamics where targeted therapies draw significant interest. Overall, these updates paint a vivid picture of an industry characterized by relentless innovation through scientific research, strategic alliances, and regulatory progress—all aimed at improving patient outcomes amidst evolving market demands. The industry's focus on breakthrough technologies continues to shape global health initiatives by offering new opportunities for patient care across various conditions. As companies navigate this dynamic environment marked by both promise and challenge—their ability to innovate scientifically while engaging strategically with regulators will be crucial to bringing novel therapies effectively into clinical practice where they can make meaningful impacts on patients' lives worldwide.Support the show

Der er over 331.000 danskere, der ejer en Novo Nordisk aktie alene på Nordnet, viser handelsplatformens egne tal. Novo Nordisk er dermed suverænt den mest populære aktie og Danmarks eneste folkeaktie. Selskabet har været igennem en katastrofal nedtur de senere år og gået fra en aktiekurs på over 1.000 til omkring 323 kroner. Men er det endelig ved at lysne med en Wegovy-pille, der sælger langt bedre end forventet? Vi har inviteret analytiker Søren Løntoft Hansen med til at analysere Novo Nordisk grundigt i bund og stiller to grundlæggende spørgsmål: Vender skuden for Novo Nordisk, og hvis du skulle give ét råd til den almindelige danske Novo-investor, hvad ville det så være? I studiet: Magnus Barsøe og Søren Løntoft Hansen. See omnystudio.com/listener for privacy information.

On this week's episode, Graig Suvannavejh, Tim Opler, Yaron Werber, Paul Matteis, and Brian Skorney kicked off with a review of the market, noting pressure in the XBI despite a longer-term bounce-back from trough levels, though they see biotech fundamentals as largely intact. The group also discussed the trend of reverse mergers as an alternative to traditional IPOs, along with AI's expansion and uncertain role in accelerating drug discovery. In regulatory news, the co-hosts welcomed the return of FDA advisory committee meetings, including those for Capricor and Replimune, and highlighted Anthony Fauci's recent Senate testimony on the handling of the COVID-19 pandemic. In deals, J&J struck an in vivo CAR-T partnership with Sail Biomedicines, with potential readthroughs for Legend Biotech, and Argenx is set to acquire Forte Biosciences to bolster its immunology pipeline. The group also highlighted Lilly's recent acquisition of psychedelics company AtaiBeckley, opening a broader discussion on deals in the psychedelics space. The episode concluded with company news including Alnylam shares dropping 30% following disappointing updated guidance, Novo Nordisk's Phase 3 study for its anti-IL-6 ligand antibody, and MapLight's Phase 2 schizophrenia readout. *This episode aired on July 31, 2026.

Het is een beetje een saai, ouderwets en gedateerd techbedrijf, maar tóch moet je erop letten, zegt onze gast, Jos Versteeg van InsingerGillisen. Infineon! Een Duits techbedrijf, volgens Jos in de verste verte niet vergelijkbaar met bijvoorbeeld TSMC, daar is de techniek te oud voor. Tóch vindt hij de cijfers interessant, omdat ze chips leveren voor datacenters. Daar hoopt hij meer over te horen. We kijken vooruit op de cijfers, en ook een klein beetje op die van AMD. In Beurs in Zicht stomen we je klaar voor de beursweek die je tegemoet gaat. Want soms zie je door de beursbomen het beursbos niet meer. Dat is verleden tijd! Iedere week vertelt een vriend van de show waar jouw focus moet liggen. Te gast: Jos Versteeg van InsingerGillisen BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie.See omnystudio.com/listener for privacy information.

Het is een beetje een saai, ouderwets en gedateerd techbedrijf, maar tóch moet je erop letten, zegt onze gast, Jos Versteeg van InsingerGillisen. Infineon! Een Duits techbedrijf, volgens Jos in de verste verte niet vergelijkbaar met bijvoorbeeld TSMC, daar is de techniek te oud voor. Tóch vindt hij de cijfers interessant, omdat ze chips leveren voor datacenters. Daar hoopt hij meer over te horen. We kijken vooruit op de cijfers, en ook een klein beetje op die van AMD. In Beurs in Zicht stomen we je klaar voor de beursweek die je tegemoet gaat. Want soms zie je door de beursbomen het beursbos niet meer. Dat is verleden tijd! Iedere week vertelt een vriend van de show waar jouw focus moet liggen. Te gast: Jos Versteeg van InsingerGillisen BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie.See omnystudio.com/listener for privacy information.

Episode SummaryEric Ries is the author of The Lean Startup and The Startup Way, and the founder of IMVU and the Long-Term Stock Exchange. His new book, Incorruptible, examines why companies drift from their mission once investors and boards take over, and what founders and early investors can do to prevent it.In this episode, Cheryl and Maxine unpack what Eric calls "financial gravity," the force that pulls companies toward extractive, value-destroying behavior even when everyone believes they're pursuing profit. Eric explains why many widely taught governance best practices are actually shareholder-value destroying, and why the earliest stage of a company is the easiest time to build in protections against this drift.You'll also hear Eric break down the "spiritual holding company" structure, using Novo Nordisk's century-old nonprofit foundation as an example of why mission-guardian structures make companies far more likely to survive long term. The conversation covers why founders get talked out of protective provisions until it's suddenly too late, and Eric shares the real story of a startup that took a million dollars from Purdue Pharma to push opioids to doctors, and why it destroyed the company.He closes with his Big Cojones moment: a board meeting early in his career where he expected to be fired for refusing to abandon his unconventional methods, and the lesson that "harder is easier" when you stand for something you believe in.Time Stamps00:00 – Intro04:10 – Eric's first investment: putting his own money into IMVU's friends and family round09:15 – From Lean Startup to Incorruptible: why it's always felt like one continuous project to Eric17:40 – The tortilla company, private equity, and why "pricing power" explains so much bad behavior21:30 – Why so-called governance best practices are often value destroying25:50 – Naming the problem: financial gravity and why our grandparents would have called it corruption30:20 – What founders and early investors can actually do at the earliest stage36:45 – The Olympic athlete analogy: why protective structures only work if built in early41:10 – The spiritual holding company explained through Novo Nordisk's origin story48:30 – Why companies rated for "good governance" have underperformed since 200852:15 – The Purdue Pharma story and how a million dollars destroyed a company58:40 – Big Cojones moment: the board meeting Eric thought would get him firedSponsors:First Cheque is supported by our wonderful sponsors:Deel: Founders scale faster on Deel. Set up payroll for any country in minutes, hire anyone anywhere, and get visas handled fast, so you stay focused on scaling. Deel takes care of onboarding, HR, IT, EOR, benefits, and compliance, so your team can grow without borders.It's why more than 40,000 fast-growing companies trust Deel to move fast.Visit https://www.deel.com/dayone___Pear Tree: Pear Tree helps Australian and New Zealand founders build high-performing offshore teams without the agency middleman.As local hiring becomes more expensive and harder to fill, many operators are turning to offshore talent across engineering, development, marketing, accounting and operations at a fraction of local salary costs.The offshore horror stories you hear usually aren't a talent problem. They're the result of outsourcing agencies that overcharge clients while underpaying staff. Pear Tree takes a different approach through a direct, transparent model where your team is paid fairly, fully compliant, and focused entirely on your business.As part of the Day One community, you'll receive a free team audit to identify where offshore talent could move the needle in your business, plus 20% off your first hire. Learn more at http://dayone.fm/peartreeFirst Cheque is part of Day One.Day One helps founders and startup operators make better business decisions more often. To learn more, join our newsletter to be notified of new First Cheque episodes and upcoming shows.Mentioned in this episode:Pear TreeIf you're a founder or operator trying to scale, here's the reality — Australian hiring is getting harder, salaries are at record highs, and the talent you need is increasingly out of reach. The best operators are quietly building offshore teams of engineers, marketers, accountants and analysts at a fraction of the cost. Pear Tree does it differently. We headhunt highly skilled talent from the Philippines and South Africa with full transparency on where every dollar goes, so your team is paid fairly and fully focused on your business. As a Day One listener, you'll receive a free team audit to identify where offshore talent could move the needle in your business, plus 20% off your first hire.Deel x PX_Script 1Pear TreeIf you're a founder or operator trying to scale, here's the reality — Australian hiring is getting harder, salaries are at record highs, and the talent you need is increasingly out of reach. The best operators are quietly building offshore teams of engineers, marketers, accountants and analysts at a fraction of the cost. Pear Tree does it differently. We headhunt highly skilled talent from the Philippines and South Africa with full transparency on where every dollar goes, so your team is paid fairly and fully focused on your business. As a Day One listener, you'll receive a free team audit to identify where offshore talent could move the needle in your business, plus 20% off your first hire.This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrpSpotify Ad Analytics - https://www.spotify.com/us/legal/ad-analytics-privacy-policy/

It'll be another busy week of corporate earnings releases too, with close to 140 more S&P 500 companies scheduled to report. A wide range of sectors will be represented, with some of the highlights likely to be Caterpillar, McDonald's,Disney, Uber and Republic Services. SpaceX will announce its inaugural result as a listed company, while we'll also hear from healthcare heavyweights Eli Lilly and Novo Nordisk.

U.S. Treasurys popping to end the week as the 2 Year hits a near two-decade high and the 10 Year reaches highs not seen since January 2025. The traders break down the reason behind the surge and if this could affect the next Fed rate decision. Then, Novo Nordisk tumbling after a heart medicine trial failure. Mizuho securities healthcare sector specialist Jared Holz lays out how the company can coarse correct, and what this means for the broader pharmaceutical space. Plus, Amazon surging 15% on the back of its earnings while Exxon loses steam, and counting down to SpaceX's earnings report as the aerospace giant trades well below its IPO price. Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Is biotech taking a trip to the world of psychedelic drugs? Why is Novo Nordisk going after Eli Lilly’s Zepbound ads? And what are peptides? This week on "The Top Line," Fierce's Zoey Becker, Will Maddox and Kevin Dunleavy chat about some of the biggest recent stories. From a psychedelics acquisition that could spark more movement in the emerging field to an advisory committee meeting on peptides shrouded in political controversy to a lawsuit between the two major obesity drugmakers, we’ll catch you up on the latest developments shaking up the biopharma world. To learn more about the topics in this episode: ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback Novo Nordisk files lawsuit accusing rival Eli Lilly of running ‘false and misleading’ GLP-1 ads Novo escalates Lilly false advertising suit with planned bid to halt comparative ads See omnystudio.com/listener for privacy information.

Das echtgeld.tv-Depot steht aktuell bei 422.017 Euro. Seit dem letzten Depot-Update Anfang Juni hat es 3,6 Prozent zugelegt und damit den breiten Welt-ETF geschlagen. Seit dem 19. Dezember fällt das Bild allerdings anders aus! Tobias Kramer erklärt, welche Rolle die geringere Technologiegewichtung dabei spielt, warum er sich mit seiner Allokation und dem Risiko-Management dennoch wohlfühlt und wo er jetzt neues Kapital investiert. Im Mittelpunkt stehen mehrere konkrete Portfolio-Entscheidungen: • Aus dem Tabakdepot fließen 607 Euro Dividenden zurück in Imperial Brands. Tobias kauft 18 weitere Aktien und setzt damit erneut auf die aus seiner Sicht attraktivste Bewertung unter seinen fünf Tabakwerten. • Das Gesundheitsportfolio wächst über drei ETF-Sparpläne weiter: MSCI World Healthcare, MSCI Europe Healthcare sowie Medical Robotics and Bionic Engineering. • Die Übernahme von TruBridge ist abgeschlossen. Aus dem ursprünglichen Einsatz von rund 1.200 Euro wurde eine Gutschrift von gut 2.600 Euro. Aber, da wird es noch ein Update geben! • Im DAX-Portfolio investiert Tobias die erhaltenen Dividenden neu. Für die bislang kleinste Position Henkel stellt er eine Limit-Order über sieben Aktien zu 75,75 Euro ein. • PayPal, Shimano, Fresenius und Novo Nordisk sorgten in den vergangenen zwei Monaten für deutlichen Rückenwind. Bei PayPal treiben zusätzlich die Übernahmegerüchte den Kurs. • Samsung verliert seit Anfang Juni knapp 28 Prozent. Tobias bleibt dennoch investiert und erklärt, warum die Aktie auf Basis der aktuellen Gewinnschätzungen weiterhin außergewöhnlich günstig erscheint. • Bei Hermès nutzt Tobias den jüngsten Kursrückgang und verdoppelt seine Position. Die Aktie liegt fast 50 Prozent unter ihrem früheren Höchststand, bleibt mit einem erwarteten KGV von rund 30 aber anspruchsvoll bewertet. • Außerdem geht es um SAP auf der Watchlist, die langfristige Entwicklung des Tabakdepots sowie die jüngsten Rückgänge bei 2G Energy, Palantir und Energiekontor. Welche der im Video genannten Aktien würdet ihr auf dem aktuellen Kursniveau aufstocken – und warum?

Text: Diese Woche gab es an der Nasdaq einen Turnaround. Wie nachhalrtig dieser sein könnte, analysieren Rüdiger und Robert.Erwähnte Titel: SK Hynix, Micron, AMD, Intel, Oracle, Qualcomm, Microsoft, Meta, Apple, Mastercard, Novo Nordisk, Reddit, SpaceX, Tesla, VW, Porsche, Mercdes, BMW, RBI, Erste Group, Deutsche Bank, OMV, Shell, Airbus, Boeing, Kapsch TrafficcomDieser Podcast wird unterstützt von Raiffeisenfonds, einer Marke der Raiffeisen Kapitalanlage GmbH. Über Geld zu reden ist wichtig, um finanzielle Transparenz und Verständnis zu fördern. Es hilft, Missverständnisse und Konflikte zu vermeiden und gemeinsame finanzielle Ziele zu setzen. Offene Gespräche über Geld ermöglichen es, Wissen zu teilen und voneinander zu lernen, was zu besseren finanziellen Entscheidungen führt. Zudem kann es helfen, finanzielle Ängste abzubauen und Unterstützung bei finanziellen Herausforderungen zu finden. Geldgespräche sind der Schlüssel zu finanzieller Gesundheit und Sicherheit. Mehr auch unter raiffeisenfonds.at, Prospekte beziehungsweise Basisinformationsblätter auf www.rcm.at unter der Rubrik „Kurse und Dokumente.Alle Folgen finden Sie auch auf KURIER.at und kronehit.at.Weitere Podcasts finden Sie unter KURIER.at/podcasts Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Biogen has made a significant acquisition by purchasing Apellis Pharmaceuticals, a move expected to boost its 2026 revenue guidance with promising growth prospects. This strategic acquisition, along with strong sales from new drugs, enhances Biogen's position in the competitive market for neurological disorders. By integrating Apellis' offerings, Biogen is poised to strengthen its portfolio, particularly in areas of unmet medical need. On the regulatory front, AbbVie has achieved a milestone with its drug Rinvoq (upadacitinib), which has received dual approvals from the European Union for treating non-segmental vitiligo and severe alopecia areata. These approvals were based on successful Phase 3 data, underscoring Rinvoq's efficacy as a JAK inhibitor in tackling autoimmune conditions. This development not only highlights AbbVie's commitment to expanding its therapeutic portfolio but also positions upadacitinib as a potential mainstay treatment for dermatological autoimmune diseases. AstraZeneca Pharma India has secured approval from the Central Drugs Standard Control Organization for Enhertu (trastuzumab deruxtecan) in the neoadjuvant setting for HER2-positive early breast cancer. This approval marks a significant advancement in personalized cancer therapy, offering new hope for patients with this aggressive form of breast cancer. In terms of industry collaborations, the landscape is witnessing numerous partnerships and strategic alliances that are driving innovation forward. Skyverna Therapeutics and ElevateBio have entered a five-year clinical and commercial supply agreement for autoimmune CAR-T therapy, reflecting the growing interest in cell therapies for rare diseases. Meanwhile, Vertex Pharmaceuticals and AbCellera have joined forces to accelerate drug discovery in autoimmune T-cell engagement, supported by a $28 million upfront investment. These collaborations emphasize the importance of combining expertise and resources to advance complex therapeutic solutions. The integration of artificial intelligence in drug development continues to gain momentum. Evinova and Merck KGaA's strategic collaboration aims to leverage AI and machine learning to enhance clinical trials' efficiency, potentially ushering in a new era of precision medicine. Such partnerships highlight the transformative potential of AI in streamlining research and development processes. In funding news, Core Biomedicine has secured $21 million in Series A financing to advance its precision oncology therapeutics. Enlivex's substantial $400 million private placement aims at advancing prediction markets treasury and Allocetra immunotherapy, further accentuating the focus on personalized medicine targeting specific cancer pathways. Clinical trials have also delivered promising results. ProMIS Neurosciences reported positive interim safety and biomarker data from its Phase 1b study of PMN310 for Alzheimer's disease. This monoclonal antibody targets amyloid-beta oligomers implicated in Alzheimer's pathology, offering hope for patients with this debilitating disorder. Mergers and acquisitions remain active, exemplified by Caldera Therapeutics' reverse merger with Synlogic alongside $278 million in financing to advance its bispecific antibody for inflammatory bowel disease. This move reflects a broader trend toward consolidating resources to tackle complex autoimmune conditions. Eli Lilly's ascent to the top of Norstella's pipeline-to-patient productivity index is noteworthy, driven by successful launch strategies and rapid development cycles. This achievement underscores Eli Lilly's effective alignment of R&D efforts with market needs, particularly in areas such as GLP-1 receptor agonists that have transformed diabetes care. Teva Pharmaceuticals is demonstrating resilience through its innovative medicines portfolio amidst declining generic sales. The unexpected surge in Ajovy sales highlights Teva's pivot toward high-value branded drugs amidst competitive pressures. Novo Nordisk faces legal challenges as it navigates allegations regarding Cagrisema's Phase 3 study protocol changes. Legal scrutiny around transparency in clinical trial disclosures continues to highlight the importance of ethical practices and investor trust. Collectively, these developments illustrate a vibrant yet challenging environment where scientific advancements in immunotherapy and targeted treatments intersect with strategic business alignments focused on sustainable growth. As these trends unfold, they promise more effective treatments for complex diseases while companies adapt to an evolving market environment demanding agility and foresight. As always, stay tuned to Pharma Daily for more insights into how these transformations continue to shape the future trajectory of drug development and healthcare delivery globally.Support the show

Týždenné spravodajstvo z finančných trhov.Súboj o trh s liekmi proti obezite sa vyostruje – Eli Lilly preberá iniciatívu pred Novo Nordisk, zatiaľ čo celý segment GLP-1 terapií pokračuje v rekordnom raste. O jeho dlhodobom potenciáli svedčí aj záujem Samsung Biologics, ktorý chce prostredníctvom akvizície PolyPeptide profitovať z rastúceho dopytu po výrobe peptidových liekov. Téme sa vo svojom týždňovom komentári z finančných trhov podrobnejšie venuje Adam Záhorský...IAD TALKS, týždenník, IAD Investments,správ. spol., a.s., Malý trh 2/A, 811 08 Bratislava, IČO: 17 330 254, dátum vydania: 27.07.2026, 36/2026, EV 139/23/EPP..*UPOZORNENIE. Tento materiál je marketingovým oznámením. Kompletné znenie upozornenia nájdete na stránke www.iad.sk/marketingoveoznamenia

Deuxième partie de notre sélection des 10 actions prometteuses pour le second semestre. Guy Legrand  et Gaële Poncelet analysent le potentiel de Novo Nordisk, Cameco, Campine, IBA, Kinepolis et Xior. Entre valeurs de rattrapage, leaders de long terme et pépites belges méconnues, découvrez les opportunités qui pourraient marquer les prochains mois en Bourse. Vincent Juvyns clôture l'épisode avec une réflexion sur l'épargne des Belges et son rôle dans l'économie. Trends Bourse est une chaîne podcast de Trends-Tendances. Plus d'informations et de conseils pour vos investissements sur www.tendances.be/bourse. Vous désirez recevoir chaque jour des conseils d'investissements dans votre boîte électronique, enregistrez-vous gratuitement sur www.tendances.be/newsletters. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Host: Rasha Al-Lamee Guests: Christina Magnussen Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2559   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartis, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Risk factors and longevity in women and in men  Mythbusters: Smartphone interference with pacemakers, ICDs Host: Rasha Al-Lamee Guests: JP Carpenter, Christina Magnussen Want to watch that episode? Go to: https://esc365.escardio.org/event/2559 Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartiq, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

The Ukrainian President Volodymyr Zelensky has fired his army commander-in-chief, Oleksandr Syrskyi, in one of the biggest shake-ups of the country's military leadership since the start of Russia's full-scale invasion. General Syrskyi had clashed with the popular defence minister, Mykhailo Fedorov, whose own removal from office last week triggered rare mass protests in Ukraine. Also: France becomes the first country in the EU to ban children under the age of 15 from using social media. A special report from the school in Iran where 156 people, mostly children, were killed at the start of the US-Israeli war. As Venezuela's ousted leader Nicolás Maduro is due back in court in New York, Venezuelans tell the BBC they are too focused on trying to rebuild their lives after the earthquakes to give much thought to the criminal proceedings. The maker of Wegovy and Ozempic, Novo Nordisk, has launched legal action against its rival Eli Lilly, accusing it of false advertising in suggesting its weight-loss drugs perform better. Animal welfare experts in Britain are looking after a marmoset monkey that was found abandoned in a laundry bag on a London bus. And we look at the new developments in sleep health technology focusing on disease prediction.The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.ukPhoto: Ukraine's President Zelensky and now former Commander in Chief of the Ukrainian Armed Forces, Colonel General Oleksandr Syrskyi, visit an exhibition of new Ukrainian made drone-missiles Peklo in Kyiv. Credit: REUTERS/Valentyn Ogirenko

A new Gemini model is out and the AI world isn't impressed. But is this Alphabet knowing its business better than anyone else or a loss of the company's magic? Plus, we discuss Novo Nordisk suing Eli Lilly and GE Vernova's stock falling after a great earnings report. Travis Hoium, Lou Whiteman, and Jon Quast discuss: - Gemini's Model Dud? - Gemini Pro Delay - Novo Sues Eli Lilly - Novo's Desperation - GE Vernova Earnings - Energy's Peak Companies discussed: GE Vernova (GEV), Alphabet (GOOG), Novo Nordisk (NVO), Eli Lilly (LLY). Host: Travis Hoium Guests: Lou Whiteman, Jon Quast Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

#894: Miami is now more expensive than New York City. Novo Nordisk and Eli Lilly are battling it out over weight-loss ads. A new flip phone is coming and it's designed to minimize distractions by eliminating touchscreens and social media. The Big Boy train, the largest operating steam locomotive, is making its way across America to celebrate America 250. Finally, Substack is using AI to detect AI on its platform. Got difficult questions? Head to https://www.claude.ai/mbd to answer them.  Get tickets for our trivia tournament! https://caveat.nyc/events/the-morning-brew-trivia-tournament-2026-07-30  Grab tickets to our Performance Revue show! https://www.morningbrew.com/events/brew-performance-revue-2026?utm_campaign=performance_revue_2026&utm_source=mbd Subscribe to Morning Brew Daily for more of the news you need to start your day. Share the show with a friend, and leave us a review on your favorite podcast app. Listen to Morning Brew Daily Here:⁠ ⁠⁠https://www.swap.fm/l/mbd-note⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Novo Nordisk just declared legal war on Eli Lilly as the battle over GLP-1 patients intensifies. But just because patients are being fought over does not mean they are being fought for.In this episode, we break down Novo Nordisk's lawsuit accusing Eli Lilly of misleading patients through advertisements comparing Zepbound and Mounjaro with Wegovy and Ozempic. The fight is not simply about which medication produces more weight loss. It is about who controls the information patients receive, which evidence gets highlighted, and what gets left in the fine print.Then we examine STAT News' investigation into LifeMD, a major telehealth company promoted by Novo as a legitimate pathway to GLP-1 treatment. Former employees alleged providers were pushed to process patients at breakneck speed, sometimes reviewing as many as 25 cases per hour, while refill queues, dose increases and patient messages piled up. LifeMD strongly disputes those allegations.But this cannot become another simplistic story about telehealth being bad.More than 100 million Americans are living with obesity, and only a small number of clinicians have dedicated obesity medicine expertise. The traditional healthcare system does not have enough specialists, appointment slots or geographic reach to provide every patient with an ideal, hour-long consultation.So how altruistic can we afford to be about access?Can we demand a perfect standard of care that most patients will never be able to reach? Or does scaling treatment too aggressively risk turning patients into transactions inside a prescription machine?Access cannot become a shield for negligence. But perfection cannot become another form of gatekeeping.The patient is being fought over. This episode asks what it would actually mean to fight for them.Learn more and follow On The Pen: https://www.otplinks.comThis episode is sponsored by VoaFit, where I receive care for obesity and metabolic health. https://www.voafit.com/otp to learn more!

Market update for July 22, 2026Check out the Public app for incredible investing tools and to support the show (LINK)Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In today's episode, Zaid covers:Chip stocks bounce back, but rising oil prices and new tariffs are building inflation pressureSpaceX sets its first earnings and massive share unlock as short sellers pile inNovo Nordisk sues Eli Lilly over weight-loss drug adsSuper Micro surges on stronger margins and record AI server demandGE Vernova drops despite raising its outlookKraft partners with Mickey Mouse to recharge growth 

Plus, Eli Lilly sued by Novo Nordisk... An Indianapolis woman threatens to kill a member of CongressSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

1% Bonus und eine Beteiligung an Anthropic. Das gibt's grad beim BlackRock Private Equity Fund im Broker von Scalable Capital. Mehr Infos hier. Hasbro hebt Prognose dank Magic. 3M drückt 350 neue Produkte raus. Intersnack kauft US-Snackfirma Utz für 2 Mrd. $. NVIDIA hält fast 10% an Nebius. Biotech-IPOs boomen mit 55% Rendite. Jamie Dimon warnt. Novo Nordisk klagt. Chip-Aktien steigen. Einen Dollar für 50 Cent kaufen. Das koreanische Spieleunternehmen Gravity (WKN: A14SPA) sitzt auf 400 Mio. $ Cash, ist aber kaum mehr wert. Jetzt kommt die erste Dividende ever. Startschuss für den Abbau des Cashbergs? Coca-Cola (WKN: 850663) bringt seinen indischen Abfüller 2027 an die Börse. Bewertung: 10 Mrd. $. Gleichzeitig greift Indiens reichster Mann mit einer 10-Cent-Cola an. Reliance Industries (WKN: 884241) als Indien-Wette? Diesen Podcast vom 22.07.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Hinweis: Es gelten Teilnahmebedingungen. Kapitalanlagen bergen Risiken. Es bestehen Liquiditätsbeschränkungen. Bitte beachte die spezifischen Produktinformationen. Teilnahmebedingungen: www.scalable.capital Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent advancements in these sectors highlight a fascinating intersection of technology and medicine, underscoring a push towards innovation that promises to reshape healthcare delivery. Bristol Myers Squibb has expanded its collaboration with NVIDIA, aiming to create what could become the most powerful AI infrastructure dedicated to life sciences. This partnership is set to harness artificial intelligence and machine learning technologies to revolutionize drug discovery and development. By enhancing data analysis and predictive modeling, this collaboration may lead to more efficient identification and validation of drug targets, reflecting a growing industry trend towards leveraging AI to streamline R&D processes. In infectious diseases, Gilead Sciences and Merck & Co. have reported promising phase 3 clinical trial results concerning their combination therapy for HIV treatment. This regimen, combining islatravir and lenacapavir, could become the first weekly oral medication for HIV, offering a significant improvement over daily treatments. Such developments not only promise enhanced patient adherence but also mark a pivotal step forward in long-term HIV management by potentially increasing quality of life for patients. Oncology diagnostics are also seeing significant strides as Tempus AI plans to acquire Personal Genome Diagnostics for $1.5 billion. This acquisition is poised to bolster Tempus's portfolio in cancer minimal residual disease diagnostics. The integration of capabilities from Personal Genome Diagnostics is expected to enhance precision oncology efforts, providing more comprehensive data for personalized cancer treatment plans. Regulatory updates bring more promising news with Takeda's dengue vaccine, Qdenga, securing approval in India. This live-attenuated vaccine targets all four serotypes of the dengue virus, representing a major advancement in regions burdened by dengue fever. Similarly, JCR Pharmaceuticals has received marketing authorization in the UAE for Izcargo, an enzyme replacement therapy that penetrates the blood-brain barrier to treat Hunter syndrome, showcasing innovations in treating rare genetic disorders. Strategic partnerships continue to be a focal point in industry growth. Menarini Asia-Pacific has joined forces with Pharmacosmos to commercialize Cosela across Asia-Pacific regions. Additionally, Halozyme Therapeutics has partnered with Incyte on subcutaneous formulations of a monoclonal antibody using their proprietary Enhaze technology, highlighting advancements in drug delivery systems. Financially, Novartis has shown resilience by returning to sales growth driven by products like Kisqali and Kesimpta amidst generic competition challenges. Meanwhile, Axiom Biosciences is gearing up for an IPO in Hong Kong, indicating a growing interest in stem cell therapies for neurological and rare diseases. Yet not all news has been positive. Novartis has discontinued its phase 2 radioligand therapy targeting gastrin-releasing peptide receptors due to underwhelming results in solid tumors. Agios Pharmaceuticals has similarly halted development of its pyruvate kinase activator for sickle cell disease following unsatisfactory phase 2 data. Legal battles continue as well, with Novo Nordisk suing Eli Lilly over GLP-1 agonists efficacy claims and Moderna locked in patent disputes with CureVac over COVID vaccine technologies. These stories reflect dynamic shifts emphasizing innovation through AI collaborations and novel therapeutic developments in HIV and oncology treatments. They also highlight strategic acquisitions enhancing diagnostic capabilities while revealing challenges such as competitive pressures and regulatory hurdles that companies must navigate. Turning our attention back to scientific breakthroughs, Jennifer Doudna's venture into AI-powered protein design underscores how artificial intelligence continues transforming biotechnology. Her exploration highlights AI's potential to accelerate drug discovery by enabling more precise targeting of disease-related proteins. Additionally, recent successes in personalized medicine include the establishment of a new center dedicated to genetic therapies. Spearheaded by leading scientists, this initiative aims at developing tailored treatments based on individual genetic profiles—advancing precision medicine and reducing adverse effects. In conclusion, these developments illustrate a vibrant landscape where scientific breakthroughs intersect with strategic business maneuvers. As companies navigate these complex waters—balancing innovation with regulatory scrutiny—they continue pushing boundaries that promise improved patient outcomes worldwide while reshaping future healthcare landscapes.Support the show

Markets faced a fresh wave of geopolitical risk as the conflict involving the US, Iran and the Houthis escalated, pushing oil prices higher. Yet equities remained resilient, with positive corporate earnings and strength in semiconductors helping offset investor concerns. Elsewhere, the US announced a 50% tariff on a broad range of Canadian imports, Japan's yen weakened beyond 163 against the dollar despite intervention warnings, and competition intensified in the obesity drug market as Novo Nordisk sued Eli Lilly. Investors now await results from Alphabet and Tesla while continuing to monitor developments in the Middle East. We are also joined by Dario Messi, Head of Fixed Income Research, to discuss what to expect from tomorrow's ECB meeting and whether higher oil prices could prompt the ECB to adopt a more hawkish stance.(00:00) - Introduction: Jan Bopp, Product & Investment Content (00:48) - Markets wrap-up: Lucija Caculovic, Product & Investment Content (07:56) - Fixed income update: Dario Messi, Head of Fixed Income (11:07) - Closing remarks: Jan Bopp, Product & Investment Content Would you like to support this show? Please leave us a review and star rating on Apple Podcasts, Spotify or wherever you get your podcasts.

Der er én kæmpe joker i spil, når Novo Nordisk med Mike Doustdar præsenterer halvårsregnskab om to uger. Selskabet nye fedmepille kommer til at fylde det hele, og helt nye recepttal gør ikke spændingen mindre. Analytikerne håber på en opjustering - alt andet vil være en skuffelse. Hør i denne Lyn-analyse, hvad de nye recepttal indikerer og hvor konkurrenten Eli Lilly er med deres modtræk, Fundayo-pillen. Gæst: Lone Andersen, journalist, Finans. Vært: Mads Ring. Foto: Novo Nordisk.See omnystudio.com/listener for privacy information.

P.M. Edition for July 21. Recent AI models from China claim they're just as powerful as some of the most cutting-edge models from OpenAI and Anthropic. Journal reporter Amrith Ramkumar joins to discuss the latest reactions from Silicon Valley and the White House. Plus, General Motors had a strong second quarter as consumers kept buying pickup trucks and SUVs. And New Jersey says a software error led to almost 400 non-citizens voting in elections in the state since 2023. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Novo Nordisk files a deceptive advertising lawsuit against Eli Lilly. And the latest Chinese AI model launches rattle expectations for the biggest AI players in the US. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Carl Icahn's company agrees to sell auto-service chain Pep Boys. And Ukraine strikes a deal with defense company BAE Systems to manufacture howitzers locally. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carl Quintanilla and Jim Cramer discussed the chip sector rally as stocks look to snap a three-day losing streak. Hear why Cramer says not to own "too much tech" and that "for the moment, it's time to go to other sectors." The anchors reacted to 3M and General Motors each posting Q2 earnings beats and raising guidance. SpaceX in the midst of a seven-day losing streak and falling below Meta in the market cap race. See how far SpaceX shares have tumbled since being added to the Nasdaq 100 two weeks ago. Also in focus: Oil rises on U.S.-Iran tensions, President Trump hits Canada with 50% tariffs, Nvidia's 9.3% stake in Nebius, Novo Nordisk sues weight-loss drug rival Eli Lilly, Oracle's credit risk and AI debt, earnings winners and losers.   Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Jimmy Chang, CIO at Rockefeller Global Family Office, explains why the AI capex boom continues to support the market but argues investors should wait for more earnings commentary before adding to semiconductor positions. Plus, pressure in enterprise software after a Salesforce downgrade and the spike in Oracle's credit default swaps. Our Angelica Peebles reports on Novo Nordisk's lawsuit against Eli Lilly over Zepbound advertising and what the legal battle could mean for the obesity drug market. Jay Jacobs, U.S. Head of Equity ETFs at BlackRock, discusses the firm's new IQQ ETF and how investors are gaining exposure to the Nasdaq 100. EQT CEO Toby Rice explains the outlook for natural gas and energy demand. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Novo Nordisk Group General Counsel & Senior Vice President John Kuckelman speaks with Bloomberg's Dani Burger and Isabelle Lee after the company on Tuesday accused rival Eli Lilly of misleading advertising. Novo says that Lilly’s advertising campaigns rely on outdated weight-loss comparisons with lower doses of Novo’s own obesity shot Wegovy than what’s currently available, according to the complaint.See omnystudio.com/listener for privacy information.

Jamie Dimon gaat Warren Buffett achterna. Ook hij vindt dat er geen goede aankopen meer te vinden zijn op de beurs. Al jaren dramt Dimon bij elke cijferpublicatie van zijn bank dat er een lange lijst aan risico's boven de markt hangt. Geopolitieke spanningen, instabiele inflatie, expoloderende staatsschulden: de kans is groot dat ze niet voldoende worden ingeprijst, denkt Dimon. Moet jij hem daarin volgen? Dat hoor je in deze aflevering. We hebben het ook over Samsung. Die maken al chips, koelkasten, televisies, telefoons, en nog veel meer. Maar het is allemaal niet genoeg. Ze gaan nu ook aan de humanoïde robots. Er wordt een aparte divisie voor opgezet, onder leiding van een van de co-CEO's zelf. Gaan ze de concurrentiestrijd met bijvoorbeeld Tesla winnen? Verder hoor je ook over een poging van de Londense beurs om weer aandacht te krijgen. Daarom gaan ze de openingstijden flink verbreden. Ze willen eigenlijk handel 24 uur per dag mogelijk maken. En we vertellen je hoe de strijd tussen farmaceuten Novo Nordisk en Eli Lilly nu naar de rechtszaal wordt verplaatst. Te gast: Thomas Pellegrom, van ABN Amro MeesPierson BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie.See omnystudio.com/listener for privacy information.

Healthcare companies are built to improve patients' lives. So why do so many prioritize shareholders over the people they're meant to serve?This week, Halle sits down with Eric Ries, author of Incorruptible, to unpack the rise of shareholder primacy, what it is, and why he believes it's at the root of many of society's biggest challenges. They discuss the surprising history of corporate governance, the lessons behind Novo Nordisk's century-long success, and what founders can do today to keep their companies aligned with their mission as they grow.We cover:Why shareholder primacy reshaped corporate America (and where we go from here)How Novo Nordisk's unusual ownership structure may have saved GLP-1 researchThe simple governance change that could preserve your company's mission for decadesHow boards, investors, and acquisitions can slowly pull companies away from their original purposeThe founder mistakes that make mission drift almost inevitableAbout our guest:Over the last two decades, Eric Ries's ideas about continuous innovation, long-term thinking, governance, and market reform have reshaped company building and management practices. He is the creator of the Lean Startup method, and the author of two New York Times bestsellers The Lean Startup and Incorruptible; The Leader's Guide; and The Startup Way. As a founder, he has put his own ideas into practice with The Long-Term Stock Exchange (LTSE); Answer.AI, an AI R&D lab; Virgil, a legal services startup; and IMVU. On The Eric Ries Show, he talks with world-class technologists, thought leaders, and executives building for the long-term. Check out his book, Incorruptible: Why Good Companies Go Bad…and How Great Companies Stay Great—

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of industry-shaping events, reflecting the ever-evolving landscape of drug development, regulatory challenges, and strategic maneuvers. In a significant move within the sector, Jasper Therapeutics has merged with Kira Pharmaceuticals, a strategic decision aimed at expanding its footprint in autoimmune therapeutics. This merger brings to Jasper a valuable asset in KP-104, a dual-inhibitor with the potential to address rare diseases—an area of considerable unmet need. Such consolidations highlight an industry trend where companies seek to bolster their portfolios with promising candidates that can tackle complex medical conditions. The merger exemplifies how strategic expansions are becoming increasingly integral to maintaining competitive edges in the biotech arena. Turning to clinical trials, Takeda's Zasocitinib has demonstrated promising results for patients suffering from moderate-to-severe plaque psoriasis. In Phase 3 trials, a significant 75% of patients achieved clearance of scalp psoriasis. Zasocitinib operates as a TYK2 inhibitor, targeting the IL-23 pathway—a crucial mechanism in autoimmune diseases like psoriasis. This breakthrough promises to enhance patient care by providing a more effective treatment option for those struggling with difficult-to-treat psoriasis. On the regulatory front, Novartis' Fabhalta (Iptacopan) has gained FDA approval for its role in slowing kidney function decline in patients with primary immunoglobulin A nephropathy. As a small molecule complement inhibitor, Iptacopan introduces a novel treatment class for this autoimmune kidney disorder. This approval underscores ongoing innovation within nephrology and offers renewed hope for improved patient outcomes. Recent regulatory updates also saw Novartis securing full FDA approval for Fabhalta—an affirmation of progress in addressing immunoglobulin A nephropathy through innovative therapeutic options. Business development remains a driving force in shaping industry landscapes. The acquisition of Mission Therapeutics' AKI candidate MTX652 by Dimerix is a prime example. This $5 million deal, with potential milestones up to $292 million, reflects high stakes and ambitions to advance treatments for acute kidney injuries—a field with significant unmet medical needs. The integration of artificial intelligence continues to revolutionize drug discovery processes. Aqemia's collaboration with Sanofi highlights this trend, showcasing AI's crucial role in expediting drug development and uncovering novel therapeutic targets. Their partnership potentially worth $140 million underscores AI's transformative potential within pharmaceutical research. Notably, Nobel laureate Jennifer Doudna's foray into AI-powered protein design signifies an exciting intersection between gene-editing technology and artificial intelligence. Her involvement signals potential revolutions in drug discovery through enhanced precision in protein engineering. However, regulatory challenges persistently loom over the industry. Novo Nordisk and Alvotech have faced FDA scrutiny concerning manufacturing deficiencies—an issue that accentuates the importance of stringent quality control and operational excellence in biologics manufacturing. The American Society of Health-System Pharmacists (ASHP) report on U.S. drug shortages during Q2 2026 reveals vulnerabilities within supply chains, notably impacting oncology drugs. These shortages emphasize the critical need for robust strategies to ensure consistent drug availability for essential therapies. Furthermore, geopolitical dynamics are influencing pharmaceutical supply chains. A U.S. Senate bill aimed at increasing transparency highlights concerns over China's dominance in drug ingredient supplies—an issue necessitating strategic adjustments by globally operating companies. Elsewhere within the sector, GSK made headlines by discontinuing the development of its chronic cough treatment camlipixant following mixed Phase 3 trial results—a setback illustrating the critical nature of trial outcomes in determining drug viability and market potential. In market trends, biotech IPOs have surged during the first half of 2026—a sign of robust investor interest fueled by innovations and favorable funding environments despite associated market volatility risks. Strategic adjustments continue across companies with mergers and acquisitions leading to workforce reductions—projected layoffs exceeding 14,000 within biopharma during H1 2026—as organizations streamline operations or pivot towards more promising research domains. Lastly, Merck's FDA approval for an oral PCSK9 inhibitor marks a significant achievement in cardiovascular care—representing another stride forward in therapeutic innovation. In summary, these developments encapsulate a landscape defined by scientific pursuits yielding mixed results amidst evolving regulatory interactions and strategic realignments—all contributing towards innovative healthcare solutions while navigating complex industry dynamics.Support the show

Can AI startups keep their promise to benefit humanity? Eric Ries explains why business success often leads to corporate "corruption" of the founder's mission.Eric Ries, creator of the Lean Startup Method, breaks down the inherent tensions between scaling a business and maintaining its core purpose. We examine why so many organizations lose sight of their initial mission as they grow, and what it takes for leadership to stay grounded.This discussion focuses specifically on how AI company ethics are being tested in the current market. Ries shares his perspective on advising Anthropic, offering a rare look at how a major firm attempts to protect its mission while navigating rapid growth. If you are interested in the intersection of philosophy and corporate strategy, this breakdown offers a practical look at the challenges modern founders face.Subscribe for weekly business strategy breakdowns, and let me know in the comments: what do you think is the biggest threat to a company's original mission?YOU'LL DISCOVER✅ Why corruption means making money without creating value, not breaking the law✅ The Sol Price story: how FedMart was liquidated, and Costco grew from the same idea✅ Why shareholder primacy is only about 40 years old, not a law of capitalism✅ The three-part formula for an incorruptible company: purpose, coherence, integrity✅ How alternative ownership structures (foundations like Novo Nordisk and Hershey, purpose trusts like Patagonia) make firms far more durable✅ Eric's idea of financial gravity and why your buying, working, and investing choices matter✅ The job interview question that can push a company to put its mission in its legal charter✅ Why Anthropic's public benefit corporation and long-term benefit trust protect its mission⏱️ TIMESTAMPS0:00 Why success corrupts good companies3:14 What corruption really means5:41 Shareholder primacy is a recent invention8:22 Sol Price, FedMart, and the founding of Costco13:08 Who decides which values matter18:22 Missionaries versus mercenaries19:44 How Google lost its way21:38 Governance structures that protect a mission28:01 Financial gravity and your power35:25 Red flags when vetting a company43:00 Why I am optimistic50:53 Advice for AI founders and AnthropicSubscribe to CXOTalk for weekly conversations with the business and technology leaders shaping the enterprise.Get the CXOTalk newsletter: https://newsletter.cxotalk.comShow notes, transcript, and summary: https://www.cxotalk.com/episode/can-you-build-an-incorruptible-ai-company-a-conversation-with-eric-riesEpisode 923 | Recorded June 26, 2026#CXOTalk #EricRies #Incorruptible #LeanStartup #CorporateGovernance #ShareholderPrimacy #MissionDriven #Leadership #Anthropic #BusinessEthics

In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über Ernüchterung bei Netflix, den finalen Atai-Moment und einen erwachenden Markt. Außerdem geht es um SpaceX, Alphabet, Oracle, Abbott Laboratories, UnitedHealth Group, J.B. Hunt Transport Services, AtaiBeckley, Eli Lilly, Compass Pathways, Definium Therapeutics, Infineon, ABB, Schneider Electric, Siemens Energy, ASML, Delivery Hero, Uber, Novo Nordisk, Burberry, Saab, Travelers, Yara, BlackRock, Goldman Sachs, JPMorgan Chase, Robinhood Markets, Reddit, Nvidia, Micron Technology, SanDisk, Applied Materials, Western Digital, KLA, Marvell Technology, Lam Research, iShares Nikkei 225 (WKN: A0YEDQ), Xtrackers MSCI Japan (WKN: DBX1MJ), Amundi Japan Topix (WKN: A2H58U), VanEck Space Innovators ETF (WKN: A3DP9J), Direxion Daily Semiconductor Bull 3X Shares / SOXL (WKN: A1C1G7) Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien *Anzeige: Eight Sleep: Der Pod 5 reguliert die Temperatur im Bett automatisch, trackt Schlaf- und Gesundheitswerte ohne Wearable und kann so zu besserem Schlaf beitragen. Mit dem Code ALLESAUFAKTIEN erhaltet ihr auf https://www.eightsleep.com/allesaufaktien bis zu 350 Euro Rabatt.* Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care. Starting with Merck & Co.'s recent FDA approval for Lipfendra, the world's first oral PCSK9 inhibitor, this marks a pivotal shift in managing hypercholesterolemia. Traditionally, PCSK9 inhibitors have been administered via injection, but Lipfendra offers a more convenient oral alternative. This could significantly improve patient adherence and outcomes by easing the administration process for those managing cholesterol levels. The drug's approval highlights a crucial advancement in cardiovascular treatment, with expectations of reaching peak annual sales of $5 billion, underscoring its market potential. In another significant development, Eli Lilly has entered the burgeoning field of psychedelic therapeutics with its acquisition of Ataibeckley for up to $3.8 billion. This move reflects a growing trend toward exploring novel therapeutic avenues for psychiatric disorders. Psychedelic compounds promise new hope for patients with depression and other mental health conditions where conventional therapies have shown limited efficacy. Eli Lilly's investment signals confidence in the transformative potential of psychedelics, which could revolutionize treatment paradigms for conditions like depression and PTSD. Turning to obesity treatment, Novo Nordisk's Wegovy pill has received European Commission approval for obesity and overweight adults. As a small molecule GLP-1 receptor agonist, semaglutide enhances satiety and reduces caloric intake. This development underscores the increasing focus on metabolic disorders and highlights the competitive landscape as companies race to dominate the weight management sector with innovative oral formulations. In oncology news, Merck & Co.'s Keytruda has achieved a milestone in becoming the first PD-1 inhibitor to demonstrate phase 3 benefits as a single agent in frontline mismatch repair-deficient endometrial cancer. This success not only reinforces Keytruda's role in oncology but also emphasizes the importance of precision medicine approaches targeting specific genetic mutations in cancer therapy. The industry is also seeing substantial financial maneuvers aimed at bolstering research capabilities and market reach. Johnson & Johnson has raised its 2026 financial guidance following Tremfya's impressive $2 billion revenue milestone with its IL-23 inhibitor for autoimmune diseases. Additionally, their strategic supply chain restructuring reflects efforts to enhance operational efficiency amid a broader U.S. manufacturing push. On the regulatory front, Johnson & Johnson received UK MHRA approval for Akeega in BRCA1/2-mutated metastatic prostate cancer, highlighting ongoing focus on precision medicine and targeted therapies in oncology. Meanwhile, Medtronic's recall of Harmony Catheter Delivery Systems due to safety concerns serves as a reminder of ongoing vigilance in medical device safety regulations. In clinical trial advancements, InnoCare Pharma's TYK2 inhibitor demonstrated efficacy in a Phase 2 trial for nonsegmental vitiligo, achieving its primary endpoint and paving the way for Phase 3 studies. This highlights TYK2 inhibition as a promising strategy for autoimmune diseases like vitiligo. Moreover, we witness movements towards public offerings with companies like Vogenx and Braveheart Bio aiming for IPOs to fund their respective drug development projects. These efforts underscore the continuous drive for capital to propel innovative therapies through clinical trials and towards commercialization. Finally, turning to regulatory updates, Sanofi has entered new chapters in mRNA patent litigation against Pfizer and Moderna, reflecting ongoing tensions over intellectual property rights within the high-stakes realm of COVID-19 vaccines and mRNA technology. The outcomes here could have far-reaching implications for mRNA-based therapeutics and vaccine development. As we look at these developments collectively, they illustrate a vibrant period for pharmaceutical and biotech companies innovating new treatments while navigating complex regulatory terrains. The implications for patient care are profound, with potential improvements in therapeutic options driven by new scientific breakthroughs and strategic industry shifts. These dynamics promise to reshape the future landscape of global healthcare delivery and pharmaceutical innovation as these trends continue to unfold.Support the show

Most founders assume that building a great product and serving customers well will be enough to protect what they have built. Eric Ries, author of The Lean Startup and the new book Incorruptible, argues that the assumption is dangerously wrong.   In this episode of Business For Good, Paul Shapiro sits down with Eric Ries to explore why successful organizations are systematically pulled toward corruption by a force he calls financial gravity. The conversation examines how short-term investor incentives, flawed governance structures, and misaligned compensation hollow out companies from the inside, often without anyone intending it. Eric explains the difference between mission-hopeful companies that merely wish to stay on course and mission-driven companies that have actually engineered structural protections into their governance.   The discussion covers why independent directors have statistically failed to prevent corporate corruption, how industrial foundation structures used by companies like Patagonia, IKEA, and Novo Nordisk produce dramatically better long-term outcomes, and why tenured voting rights could realign shareholder power with genuine stewardship. Paul and Eric also explore how the same forces corrupt nonprofit organizations, using examples from animal welfare and Eric's work with Adopt-a-Pet founder David Meyer.   Things You Will Learn: Why the most successful companies become the most vulnerable targets for corruption, and why it is a systems problem, not a people problem. How financial gravity collapses organizations over time, stripping away the qualities that made them distinctive. Why independent directors have statistically failed to prevent corporate corruption despite being the standard prescription. How industrial foundation structures produce companies that are roughly five times more likely to survive to year 50 than conventionally governed peers. Why tenured voting rights and multi-stakeholder governance could replace the broken one-share-one-vote model.   Tools & Frameworks Covered: Financial Gravity: The systemic force transmitted by financial markets that gradually pulls companies away from their founding mission toward extractive behavior, regardless of the intentions of the people involved. Mission Hopeful vs. Mission Driven: A diagnostic framework for evaluating whether an organization has genuine structural protections for its mission or is simply hoping good intentions will be enough. Constitutional Governance / Industrial Foundation Structure: A corporate governance model where an outside nonprofit foundation or purpose trust serves as mission guardian over a for-profit operating company, used by Patagonia, Novo Nordisk, IKEA, and others, with evidence showing dramatically higher longevity and financial performance. #BusinessForGood #SustainableBusiness #FutureOfFood #AlternativeProtein 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest news and insights that are shaping the landscape of patient care and drug development. The U.S. FDA has expanded the label for Pfizer and Astellas' Padcev, in combination with Merck's Keytruda, to include all muscle-invasive bladder cancer patients. This significant regulatory update broadens access to a combination therapy that merges an antibody-drug conjugate with a PD-1 inhibitor, offering enhanced treatment options for patients unable to tolerate cisplatin, a common chemotherapy drug. The decision marks a pivotal step forward in providing more inclusive and effective treatment regimens for bladder cancer. In Scotland, Roche's Columvi has been endorsed by the Scottish Medicines Consortium for use in treating relapsed or refractory diffuse large B-cell lymphoma. This approval highlights the growing importance of bispecific antibodies in oncology, which can simultaneously engage two different antigens to enhance anti-tumor responses. Such innovations underscore the ongoing transformation of cancer treatment through combination therapies. Across the Atlantic, Health Canada has approved Clinuvel's Scenesse for erythropoietic protoporphyria (EPP), a rare condition causing extreme light sensitivity. Scenesse acts as a melanocortin receptor agonist, offering photoprotection and improving quality of life for those affected by this debilitating disorder. On the business front, Bayer's strategic partnership with Apollo has secured a €3 billion equity deal for its long-acting reversible contraceptives business. This move underscores a growing emphasis on women's health and contraceptive innovation. Likewise, CMS and Insilico's collaboration aims to harness artificial intelligence for CNS drug discovery, promising to accelerate drug development through AI-driven target identification. Clinical trials continue to reveal promising developments. Eisai's Etalanetug is showing potential in reducing tau tangle biomarkers in dominantly inherited Alzheimer's disease. Similarly, Eisai and BioArctic's Leqembi subcutaneous autoinjector demonstrates comparable efficacy to its intravenous counterpart, potentially improving compliance and accessibility for early Alzheimer's patients through less invasive administration methods. Financially, Apnimed is planning an IPO to support its sleep apnea pill's commercial launch, while Velogene Biotechnology has secured Series A funding to advance its gene-editing platform. These financial activities highlight ongoing investments in innovative solutions aimed at addressing unmet clinical needs. Yet, challenges persist as well. The FDA has rejected Hengrui and Elevar Therapeutics' combination treatment for hepatocellular carcinoma for a third time, emphasizing the difficulties of meeting regulatory standards and demonstrating efficacy. Additionally, Germany's new healthcare cost-saving law has doubled pharmaceutical rebate rates, sparking industry concern over potential impacts on profitability and innovation investment. The regulatory landscape continues to evolve with the FDA proposing streamlined registration processes under the "hub-and-spoke" model to enhance transparency and security within supply chains. Meanwhile, recent FDA transparency actions have led to the release of 14 drug rejection letters, underscoring ongoing challenges in securing approvals due to stringent regulatory requirements. Geographically, emerging biotech hubs like Basel and Beijing are gaining prominence as global talent hotspots due to their conducive environments for research and development collaboration. These regions are becoming increasingly attractive for biopharmaceutical innovation. Amid fierce competition in obesity management solutions, Lilly's launch of its oral GLP-1 receptor agonist Foundayo faces stiff competition from Novo Nordisk's Wegovy pill. The race reflects broader trends toward developing patient-centric therapies that offer convenience alongside therapeutic efficacy. Intellectual property strategies are also evolving as companies employ new patent tactics to maintain competitive advantages in crowded markets. Safety remains a top priority as exemplified by Lupin Pharmaceuticals' recall of contaminated eye drops, highlighting ongoing challenges in ensuring product safety. Lastly, advancements in wearable technology offer promising improvements in patient care; however, integration into clinical practice is met with infrastructural hurdles—a sentiment echoed by healthcare professionals surveyed by the AMA. Overall, these developments paint a complex picture of scientific innovation intersecting with regulatory evolution and strategic industry adaptations aimed at enhancing patient outcomes while navigating economic pressures. As the industry evolves, stakeholders must remain vigilant and adaptable to seize opportunities and address challenges effectively.Support the show

This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer. First, we discuss Vertex’s $10 billion acquisition of Crinetics Pharmaceuticals, the company’s largest deal to date, and what it says about Vertex’s push beyond its historic strength in cystic fibrosis. We also cover growing scrutiny from U.S. lawmakers over the industry’s use of clinical trials in China. Then, Fierce Pharma Senior Editor Fraiser Kansteiner recounts his recent trip to New Orleans for the American Diabetes Association’s 2026 Scientific Sessions with Fierce Pharma Marketing’s Zoey Becker. For years, ADA has focused heavily on its eponymous indication, but this year’s meeting made clear how much the conversation is evolving, with obesity data from drugmakers of all stripes taking up more of the spotlight. Topics include the biggest data sets from the meeting, what it was like to sit down with Novo Nordisk’s new CEO for the first time and the latest from Insulet’s Marvel collaboration on a line of comics about an Omnipod-wearing superheroine. To learn more about the topics in this episode: Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’ ‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes This week's episode is sponsored by IQVIA Biotech. Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.comSee omnystudio.com/listener for privacy information.

Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.  Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

After England's World Cup game against Mexico, Will Bain speaks to one publican who's just closed up at 5am after screening the match.Separately, an interview with the prime minister of Luxembourg, who tells Wake Up to Money that a new Defence, Security and Resilience Bank should be established for NATO countries.Plus, Novo Nordisk's new once-daily weight-loss pill becomes available in the UK today - what might it do to the market?

$163,700 in 4 Months: The Fastest Way to Break Into Pharmaceutical SalesI was a professor who taught thousands of students. I noticed something: formal education doesn't guarantee a high-paying job.That's why I created Medical Sales U.Our system gets results:✓ Self-paced course✓ Online virtual coaching✓ Personal coaching from me✓ Community accountabilityLast month, our members landed offers at: Novartis, Eli Lilly, Novo Nordisk, Thermo Fisher, BaxterAverage: $163,700 compensation in under 4 months.THE COMPARISONMBA Path: $100K+ investment | 2 years | 23% unemploymentMedical Sales U: $4,997 investment | Employed under 4 months | Members landing at Fortune 500sYou could spend $100K on an MBA with no job guarantee. Or invest $4,997 in a system designed to get you hired.Apply: medicalsalesu.com#MedicalSales #PharmaJobs #CareerChange